
Akebia Therapeutics Investor Relations Material
Latest events

Q1 2025
Akebia Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Akebia Therapeutics Inc
Access all reports
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product candidate include Vadadustat, an oral therapy for the treatment of anemia due to chronic kidney disease in non-dialysis and dialysis patients; and AKB-9778, which is intended for the treatment of hypoxia-inducible factor stabilization. Its clinical programs also comprise AKB-6548, for the treatment of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis; AKB-5169 for the treatment of pain associated with osteoarthritis; and AKB-6899 for use as a bioavailable prodrug of oxaloacetate to treat disorders accompanied by oxidative stress.
Key slides for Akebia Therapeutics Inc


Investor Presentation
Akebia Therapeutics Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Akebia Therapeutics Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
AKBA
Country
🇺🇸 United States